江苏恒瑞医药股份有限公司药品申请临床试验默示许可获受理

金融界
10 hours ago

5月25日,据CDE官网消息,江苏恒瑞医药股份有限公司联合申请药品“苹果酸法米替尼胶囊”,获得临床试验默示许可,受理号CXHL2500298。

公示信息显示,药品“苹果酸法米替尼胶囊”适应症:本品联合SHR-A1811±阿得贝利单抗用于实体瘤的治疗。

江苏恒瑞医药股份有限公司,成立于1997年,位于连云港市,是一家以从事医药制造业为主的企业。企业注册资本637900.2274万人民币,实缴资本6190万人民币。

通过天眼查大数据分析,江苏恒瑞医药股份有限公司共对外投资了36家企业,参与招投标项目5000次,知识产权方面有商标信息396条,专利信息1517条,此外企业还拥有行政许可1563个。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10